BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.
Biodesix has seen its fair value estimate move from US$30.83 to US$34.00, which works out to roughly a 10% uplift in the price target range used by analysts. Recent research coverage links this shift to a mix of optimism around revenue momentum and margin potential, along with some caution about execution and the timing of profitability. As you read on, you will see how these moving parts shape the current analyst narrative and what to watch as it evolves from here. Stay updated as the Fair...
Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
This is the newest page. Registered accounts read further back.